Protalix BioTherapeutics (PLX) Misses Q3 EPS by 9c; Reports Cash and Cash Equivalents of $48.7M
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.31 +4.05%
EPS Growth %: +400.0%
Financial Fact:
NET LOSS FOR THE PERIOD: -7.29M
Today's EPS Names:
MSGM, SMID, VISL, More
EPS Growth %: +400.0%
Financial Fact:
NET LOSS FOR THE PERIOD: -7.29M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of ($0.09), $0.09 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $12.05 million versus the consensus estimate of $6.9 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
